Cardiovascular Mortality Risk Among Patients with Liver Cancer: A SEER Database Study.

IF 3.5 4区医学 Q3 ONCOLOGY Current cancer drug targets Pub Date : 2025-01-01 DOI:10.2174/0115680096321687240912111652

Juan Li, Junyong Zhang, Song He

{"title":"Cardiovascular Mortality Risk Among Patients with Liver Cancer: A SEER Database Study.","authors":"Juan Li, Junyong Zhang, Song He","doi":"10.2174/0115680096321687240912111652","DOIUrl":null,"url":null,"abstract":"Crucial for understanding liver cancer patients overall health outcomes. This research aimed to assess the CVM risk of them.Methods and materials: Data sourced from the Surveillance, Epidemiology, and End Results (SEER) database encompassing liver cancer diagnoses from 2000 to 2017 were utilized. The standardized mortality rate (SMR) was computed using general population reference data, and multivariate competing risk models were employed for analysis.Results: Analysis of 70,733 liver cancer patient records revealed 1,954 instances of CVM. The overall CVM SMR for liver cancer patients was 12.01 (95% CI: 11.48-12.55). Various demographic and clinical factors, including sex, race, age, year of diagnosis, pathological type, general stage, treatment modalities, and matrimonial status, emerged as liver cancer patients` independent predictors of CVM.Conclusion: Liver cancer patients have a notably heightened susceptibility to cardiovascular mortality (CVM) in contrast to the general populace. It is imperative to promptly recognize high-risk subcategories and execute tailored cardiovascular interventions as crucial measures to bolster survival rates within this cohort of patients.","PeriodicalId":10816,"journal":{"name":"Current cancer drug targets","volume":" ","pages":"1000-1012"},"PeriodicalIF":3.5000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current cancer drug targets","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/0115680096321687240912111652","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Crucial for understanding liver cancer patients overall health outcomes. This research aimed to assess the CVM risk of them.

Methods and materials: Data sourced from the Surveillance, Epidemiology, and End Results (SEER) database encompassing liver cancer diagnoses from 2000 to 2017 were utilized. The standardized mortality rate (SMR) was computed using general population reference data, and multivariate competing risk models were employed for analysis.

Results: Analysis of 70,733 liver cancer patient records revealed 1,954 instances of CVM. The overall CVM SMR for liver cancer patients was 12.01 (95% CI: 11.48-12.55). Various demographic and clinical factors, including sex, race, age, year of diagnosis, pathological type, general stage, treatment modalities, and matrimonial status, emerged as liver cancer patients` independent predictors of CVM.

Conclusion: Liver cancer patients have a notably heightened susceptibility to cardiovascular mortality (CVM) in contrast to the general populace. It is imperative to promptly recognize high-risk subcategories and execute tailored cardiovascular interventions as crucial measures to bolster survival rates within this cohort of patients.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

肝癌患者的心血管死亡风险：SEER 数据库研究。

这对了解他们的总体健康状况至关重要。本研究旨在评估肝癌患者的CVM风险：研究数据来自监测、流行病学和最终结果（SEER）数据库，涵盖2000年至2017年的肝癌诊断。利用普通人群参考数据计算标准化死亡率（SMR），并采用多变量竞争风险模型进行分析：对70733份肝癌患者病历的分析显示，有1954例CVM。肝癌患者的总体CVM SMR为12.01（95% CI：11.48-12.55）。各种人口统计学和临床因素，包括性别、种族、年龄、诊断年份、病理类型、一般分期、治疗方式和婚姻状况，成为肝癌患者CVM的独立预测因素：结论：与普通人相比，肝癌患者的心血管死亡率（CVM）明显增高。当务之急是及时识别高风险亚类，并采取有针对性的心血管干预措施，这是提高这类患者生存率的关键措施。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Current cancer drug targets 医学-肿瘤学

CiteScore

5.40

自引率

0.00%

发文量

105

审稿时长

1 months

期刊介绍： Current Cancer Drug Targets aims to cover all the latest and outstanding developments on the medicinal chemistry, pharmacology, molecular biology, genomics and biochemistry of contemporary molecular drug targets involved in cancer, e.g. disease specific proteins, receptors, enzymes and genes. Current Cancer Drug Targets publishes original research articles, letters, reviews / mini-reviews, drug clinical trial studies and guest edited thematic issues written by leaders in the field covering a range of current topics on drug targets involved in cancer. As the discovery, identification, characterization and validation of novel human drug targets for anti-cancer drug discovery continues to grow; this journal has become essential reading for all pharmaceutical scientists involved in drug discovery and development.